Acute myocardial infarction: pathogenesis and implications for treatment. Where do we go now?
Kawai
C
C
Department of Internal Medicine, Faculty of Medicine, Kyoto University, Japan.
D000818:Animals; D003327:Coronary Disease / Q000628:therapy*; D003328:Coronary Thrombosis / Q000503:physiopathology / Q000628:therapy*; D004730:Endothelium, Vascular / Q000503:physiopathology; D011464:Epoprostenol / Q000097:blood; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000503:physiopathology / Q000628:therapy*; D010974:Platelet Aggregation / Q000187:drug effects; D011817:Rabbits; D013928:Thromboxane A2 / Q000097:blood; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors; D014664:Vasodilation / Q000187:drug effects
D005343:Fibrinolytic Agents; D013928:Thromboxane A2; D011464:Epoprostenol; D013930:Thromboxane-A Synthase